DOVER, Del. and EPALINGES, Switzerland - December 8, 2025 - Pilatus Biosciences has been selected for the three-month entrepreneurial education program at LabCentral (Cambridge, Massachusetts, USA), the premier Massachusetts-based network of coworking labs designed to accelerate high-potential biotech startups, partnered with iPark Institute Co., Ltd. The company will participate in LabCentral’s educational program for life sciences entrepreneurs and will have the opportunity to learn from and connect with peer startups, 70+ sponsor organizations, and the broader LabCentral innovation community.

About PLT012

PLT012 is a humanized monoclonal antibody designed to selectively block CD36-mediated lipid uptake, a key mechanism driving immunosuppression and immune exclusion within the tumor microenvironment. By targeting lipid metabolism, PLT012 exerts a unique mechanism of action: it reduces immunosuppressive cell populations, including Tregs and pro-tumor macrophages, while simultaneously enhancing anti-tumor activities of intratumoral NK cell and cytotoxic CD8+ T cell that are otherwise susceptible to lipid-induced exhaustion. In preclinical studies, PLT012 has demonstrated potent monotherapy efficacy in models of liver malignancies, with a favorable safety profile across species. Leveraging its distinct mechanism of action, PLT012 further acts as a potent sensitizer in combination with anti–PD-L1 therapies, effectively overcoming drug resistance in immune “cold” tumors and liver metastases.

About Pilatus Biosciences

Pilatus Biosciences is a biopharmaceutical company developing metabolic checkpoint immunotherapies to address unmet medical needs in cancer and immune-related diseases. Founded in 2022 from the Ludwig Institute for Cancer Research, and supported by the Cancer Research Institute, Pilatus operates internationally with R&D teams in Switzerland and Taiwan. The company’s lead program, PLT012, targets CD36 to reprogram the tumor microenvironment and restore anti-tumor immunity in solid tumors.

‍

Contact:

‍‍info@pilatusbio.com‍

‍